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ABSTRACT
This article describes a number-based system for
the classification of insulin regimes. It utilizes a
patient-centered variable (number of injections
per day) and pharmacokinetic/dynamic
characteristics to craft a taxonomic system
that is able to incorporate all available insulin
preparations and coformulations. This
framework of systematics is robust enough to
include various molecules that have been
recently developed. It serves to enhance
understanding of the subject, and facilitates
the practical or clinical usage of theoretical
knowledge. We propose that number-based
insulin taxonomic models should be used in
clinical guidelines and recommendations rather
than restricting ourselves to
pharmaceutical-based classifications. PubMed
articles including both review articles and
clinical trials published since the year 1990
were searched, to gather evidence and
information on the various types of insulins
available, and how they can be used, based on
the number or frequency of injections
prescribed per day.
Keywords: Aspart; Basal insulin; BiAsp;
Coformulation of insulin; Degludec; Glargine;
Glulisine; Insulin; Intensive insulin; Lispro;
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INTRODUCTION
The term ‘‘taxonomy’’ is used to describe the
classification of various things, so the term
‘‘drug taxonomy’’ refers to the science of
listing and describing drugs, according to
various properties, in a manner which allows
easy comprehension and understanding of their
usage.
Traditionally, only pharmaceutical
properties (e.g., chemical structure and
pharmacodynamic and pharmacokinetic
characteristics) have been used to separate
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drugs into various groups. Increasingly,
however, the end user (i.e., the patient’s or
community’s perspective) is considered when
studying pharmacology [1, 2]. In the present
work, we provide a balanced, syncretic
approach to insulin taxonomy, using both
patient-centered and pharmacokinetic aspects,
to craft a number-based classification of insulin
regimes.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
CURRENT INSULIN TAXONOMY
Endocrinology and diabetology textbooks
provide comprehensive coverage of various
insulin preparations and then utilize these to
discuss different insulin regimes. The current
American Diabetes Association (ADA)/European
Association for Study of Diabetes (EASD) 2015
guidelines use the terms ‘‘basal,’’ ‘‘basal plus,’’
‘‘premixed,’’ ‘‘split-mix,’’ and ‘‘intensive’’ to
describe insulin regimes [3]. Other terms used
for regimes involving 3 or more injections per
day are ‘‘multiple’’ and ‘‘intensified’’ insulin
therapy. This drug-centered or
pharmaceutical-based terminology served
diabetology practitioners adequately in the
past; the corresponding taxonomic
methodology was able to incorporate the
limited insulin preparations available, which
included both traditional and modern insulins.
This pharmaceutical classification of insulin
regimes is not, however, syntaxic with the
current emphasis on a patient-centered
approach. It must be reemphasized here that it
is patient-centeredness which forms the basis
for recent advances in drug development and
improvements in treatment guidelines.
PATIENT-CENTERED INSULIN
TAXONOMY
Most patients of diabetes do not appreciate the
pharmacodynamic or kinetic nuances of insulin
preparations. What is more relevant to the
person requiring insulin is the number of
injections to be taken per day, the timing of
administration, and the flexibility with which
these timings can be adjusted. Based upon these
factors, it is important to craft a fresh synopsis
of insulin regimes, using the number of
injections per day as the framework for
systematic study. At the same time, such a
classification system must address the nature of
insulin preparations, whether basal, premixed,
or prandial.
Modern clinical trials are available which
support the use of premixed insulin in
once-daily and thrice-daily dosages, as
opposed to the traditional twice-daily regime.
The basal insulins detemir and glargine often
need to be prescribed twice daily in order to
achieve adequate glycemic control. Innovative
regimes utilizing combinations of rapid-acting
and premixed/coformulated insulins with
varying frequencies of administration have
also been documented. These factors also
provide important reasons to revisit current
classifications of insulin preparations.
NUMBER-BASED CLASSIFICATION
OF INSULIN REGIMES
While a number-based terminology has already
been proposed [4], it is inadequate to cover the
current range of insulin preparations and the
large number of regimens that they are used in.
With the newer insulin analogues available, a
modern, number-based classification is
required. Table 1 lists the various insulin
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regimes and preparations as well as the
frequency and timing of administration for
each. All regimes enumerated in this table are
backed by randomized controlled trials, as
shown in Table 2.
Newer ultralong-acting basal insulins and
coformulations of ultralong-acting insulin
analogues with either rapid-acting insulin
analogues, or with GLP-1RA (glucagon-like
peptide-1 receptor agonists), have recently
been introduced. While these newer
preparations are a combination of two
preparations, they definitely do not fit into the
earlier category of premixed insulins. They
differ from previous molecules in their kinetic
properties as well as their versatility. Other
molecules, such as PEGylated lispro, are also in
advanced stages of development, and will soon
be available for clinical use.
Once-daily injections include all basal,
premixed, and coformulation insulins. If
necessary, these can be used in a twice-daily
regime. Basal insulins were initially thought to
be used once a day. As NPH, glargine, and
Table 1 Insulin preparations that are currently on the market, along with the prescription patterns for them
Frequency of injection Name of regimen Insulin preparations
used
Timing of administration
1 (once a day) Basal NPH, IDet, IGlar, I
glar U300
At bedtime or the same time every
day
Basal IDeg At any time of the day
Premixed BIAsp, LisproMix With major meal
Coformulation IDegAsp With major meal
Basal ? GLP1RA IDeg ? liraglutide
IGlar ? lixisenatide
At any time of the day
2 (twice a day) Basal NPH, IDet, IGlar At bedtime and in the morning
Premixed BHI, BIAsp, LisproMix With major mealsa
Coformulation IDeg Asp With major mealsb
Basal plus Basal ? prandial At bedtime ? with major meal
3 (thrice a day) Prandial Regular, aspart, lispro,
glulisine
With meals
Bolus–bolus–premixed Prandial ? premixed With meals
Premixed–bolus–premixed Prandial ? premixed With meals
Bolus-bolus–coformulation Aspart ? IDegAsp With meals
4 or 5 (four or ﬁve times a day) Basal–bolus Any combination of
basal and bolus




Alternative to multiple injection
a Antipodal meal (i.e., meals spaced roughly 12 h apart)
b Minimum 8-h gap between 2 doses
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detemir do not provide adequate 24 h coverage,
they may need to be used twice daily in certain
patients, especially those with type 1 diabetes.
The novel ultralong-acting insulin degludec
provides adequate 24-h glycemic control and
can be used once daily at any time of the day.
These factors need to be reflected in an updated
taxonomic profile of insulin.
While basal insulins are able to achieve
adequate fasting control in many cases, they are
unable toprovideprandial coverage. Initiationof
a once-daily premix or coformulation with the
major meal or meal with highest glycemic
excursion allows control of postprandial
glucose after one meal as well. The frequency of
administration of these insulin preparations can,
if required, be intensified to twice or thrice daily.
While biphasic human insulin or premixed
analogue insulin need to be administered at
antipodal meals (i.e., meals spaced roughly 12 h
apart), IDegAsp (insulin degludec aspart) may be
administered at two consecutivemeals, provided
an 8-h gap is maintained. All of these patterns of
use find a place in a number-based umbrella of
insulin taxonomy, as opposed to the traditional
regime classification, which proposes only twice
daily use of premixed insulin.
If the twice-daily regime does not achieve
24-h euglycemia, intensive insulin therapy
(defined as that including 3 or more than 3
injections per day) may be required in the form
of either three premix insulin injections or a
basal bolus regimen. Various regimes are
available in this group. Depending upon the
needs of the patient, one can prescribe prandial
insulin thrice a day; premixed twice and
prandial once; or prandial twice and
premixed/coformulation once. Basal–bolus
regimes involving 3 bolus doses and 1 or 2
basal doses can also be used in refractory
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CONCLUSION
The number-based taxonomy is able to include
all of these regimes as subclasses (Table 1), based
upon published randomized controlled trials
(Table 2). This arrangement makes it much
simpler for the student to understand the
subject of insulin pharmacotherapeutics. It
helps the practitioner to appreciate the
versatility of insulin and the many ways in
which this life-saving molecule can be used.
This system also allows the physician to choose
the appropriate regime for a particular patient
while following person-centeredness in letter
and spirit. At the same time, choice of regime
should take biomedical factors such as severity
of hyperglycemia, risk of hypoglycemia, and
diabesity indices into account.
Such a codification would promote
appropriate choice of therapy based upon the
individual’s glucophenotype, motivation level,
and psychosocial limitations, ease of use, and
acceptance of insulin, by sensitizing the
diabetes care professional to the patient’s
needs. It also facilitates the gradual
intensification of therapy with the same
insulin.
We therefore propose that future guidelines
and recommendations utilize this
person-centered arrangement of insulin
regimes, rather than straitjacketing
preparations according to traditional criteria.
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